Novartis’ capmatinib gets FDA priority review in METex14 mutated advanced NSCLC

This article was originally published here

As per the new drug application (NDA) that has been accepted by the FDA, Novartis is seeking approval for the use of capmatinib as a treatment for first-line

The post Novartis’ capmatinib gets FDA priority review in METex14 mutated advanced NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply